Injectable treatment with long-acting cabotegravir and rilpivirine is as effective as dolutegravir-based oral treatment in adults with HIV in sub-Saharan Africa who have a history of treatment non-adherence, a three-country study reported at the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali.
Presenting the results, Dr Fiona Cresswell of the London School of Hygiene and Tropical Medicine said that long-acting treatment has an important role to play in the management of people who struggle with daily pill-taking in Africa.
Long-acting injectable cabotegravir and rilpivirine (CAB/RPV) is licensed for use in virally suppressed people. Last year, CARES, a large study conducted in Africa, reported that CAB/RPV was just as effective at maintaining viral suppression as the standard form of oral antiretroviral treatment offered through public health services.
Read the full news story at aidsmap.
All aidsmap reports from IAS 2025 can be accessed here.
SEE ALSO:
- HIV i-Base: Long-acting CAB/RPV in people with suboptimal adherence: IMPALA study results at 48 weeks
All HIV i-Base reports from IAS 2025 can be accessed here.
Source : aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.